Pritumumab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 464214576

| image =

| type = mab

| mab_type = mab

| source = u

| target = vimentin

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 499212-74-7

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = Z6Q90D1G53

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| C=6440 | H=9968 | N=1708 | O=2016 | S=42

}}

Pritumumab (PTB) is a human monoclonal antibody targeted against glioma.{{cite journal | vauthors = Babic I, Nurmemmedov E, Yenugonda VM, Juarez T, Nomura N, Pingle SC, Glassy MC, Kesari S | title = Pritumumab, the first therapeutic antibody for glioma patients | journal = Human Antibodies | volume = 26 | issue = 2 | pages = 95–101 | date = February 2018 | pmid = 29036806 | doi = 10.3233/HAB-170326 | s2cid = 3266191 }} It works by binding to the ecto-domain of vimentin on the surface of cancer cells.{{cite journal | title = International Nonproprietary Names for Pharmaceutical Substances (INN) | url = http://whqlibdoc.who.int/druginfo/INN_2004_list51.pdf | archive-url = https://web.archive.org/web/20120211194153/https://whqlibdoc.who.int/druginfo/INN_2004_list51.pdf | archive-date = 11 February 2012 | journal = WHO Drug Information | volume = 18 | issue = 1 | date = 2004 }} developed by Nascent Biotech.

It is in clinical trials for the treatment of glioma.{{cite web | url = http://www.nascentbiologics.com/news/science/70-proven-cancer-cure-back-in-the-hands-of-us-inventor-after-27-years-in-japan | title = Nascent Biologics Proven Cancer Cure Back in the Hands Of U.S. Inventor After 27 Years In Japan | date = 1 October 2009 | publisher = Nascent Biologics | archive-url = https://web.archive.org/web/20110714154240/http://www.nascentbiologics.com/news/science/70-proven-cancer-cure-back-in-the-hands-of-us-inventor-after-27-years-in-japan | archive-date = 2011-07-14 }}{{ClinicalTrialsGov|NCT04396717|Safety Study of Pritumumab in Brain Cancer}} The FDA granted orphan drug designation in 2015.

The target of Pritumumab, cell surface vimentin, has been implicated in the replication of coronavirus, specifically in Severe acute respiratory syndrome coronavirus (SARS-CoV).{{cite journal | vauthors = Yu YT, Chien SC, Chen IY, Lai CT, Tsay YG, Chang SC, Chang MF | title = Surface vimentin is critical for the cell entry of SARS-CoV | journal = Journal of Biomedical Science | volume = 23 | pages = 14 | date = January 2016 | pmid = 26801988 | pmc = 4724099 | doi = 10.1186/s12929-016-0234-7 | doi-access = free }}

PTB has been proposed as a potential treatment for COVID-19 and related Viral Infections.{{cite web | title = Race For Vaccine Intensifies As COVID-19 Second Wave of Outbreaks Threatens | date = 17 June 2020 | work = Financialnewsmedia.com | url = https://www.prnewswire.com/news-releases/race-for-vaccine-intensifies-as-covid-19-second-wave-of-outbreaks-threatens-301078296.html }}